This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 17–19, 2025 | Milan, ItalyMarch 25–26, 2025 | Digital Partnering

Brian S. Kim
Sol and Clara Kest Professor of Dermatology and Co-Founder at Icahn School of Medicine at Mount Sinai and Alys Pharmaceuticals
Speaker

Profile

Dr. Kim is the Sol and Clara Kest Professor of Dermatology, Vice Chair of Research, Director of the Mark Lebwohl Center for Neuroinflammation, and Lead of the Allen Discovery Center for Neuroimmune Interactions at the Marc and Jennifer Lipschultz Precision Immunology Institute and Friedman Brain Institute at Icahn School of Medicine at Mount Sinai. He has >180 peer-reviewed publications, multiple NIH grants, designed pivotal clinical trials that led to novel FDA-approved treatments, and is an inventor of itch-centered technologies. He has been awarded the Stephen I Katz, MD, PhD International Lectureship Award from the Society for Investigative Dermatology, Donald Y. M. Leung, MD, PhD-JACI Editors Lectureship and Faculty Development Award from the American Academy of Asthma, Allergy & Immunology, and Marion B. Sulzberger, MD Research Award and Lectureship from the American Academy of Dermatology. He is co-founder of Alys Pharmaceuticals, an immuno-dermatology biotech company and Neurommune Therapeutics, a neuroinflammation-focused biotech company. Most recently, Dr. Kim was awarded the role as the Lead of the Allen Discovery Center for Neuroimmune Interactions which is a $10 million multi-institutional center funded by the Paul G. Allen Frontiers Group and the Paul G. Allen Family Foundation.

Agenda Sessions

  • Deconstructing breakthroughs: Unpacking lessons from Alys Pharmaceuticals on advancing Immuno-Dermatology

    14:00